Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2034-2043

  Ledermann, J A ^a   Canevari, Silvana ^b   Thigpen, T ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Etarfolatide; Folate receptor; Nonsmall cell lung cancer; Ovarian cancer; Vintafolide

Indexed keywords

BGC 945; CARBOPLATIN; DEACETYLVINBLASTINE 3 CARBOHYDRAZIDE; DOCETAXEL; DOXORUBICIN; ETARFOLATIDE TC 99M; FARLETUZUMAB; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; PLACEBO; REDUCED FOLATE CARRIER; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VINTAFOLIDE; FOLIC ACID ANTAGONIST;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR LOCALIZATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); NEOPLASMS; PROGNOSIS;

CLINICAL TRIALS AS TOPIC; FOLATE RECEPTOR 1; FOLIC ACID ANTAGONISTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; PROGNOSIS;

EID: 84943764538     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv250     Document Type: Review

References (94)

1. Palumbo MO, Kavan P, Miller WH Jr et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol 2013;4: 57.
2. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012; 9: 98-109.
3. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
4. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
5. Barber EL, Zsiros E, Lurain JR et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinumresistant recurrent ovarian cancer. J Gynecol Oncol 2013; 24: 258-264.
6. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial. J Clin Oncol 2014; 32: 1302-1308.
7. Monk BJ, Pujade-Lauraine E, Burger RA. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. Ann Oncol 2013; 24(suppl 10): x53-x58.
8. Huang H, Zheng Y, Zhu J et al. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960.
9. Twu C, Han ES. Clinical utility of targeted treatments in the management of epithelial ovarian cancer. Biologics 2012; 6: 233-244.
10. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013; 31(15): 1904-1911.
11. Katsnelson A. Momentum grows to make 'personalized' medicine more 'precise'. Nat Med 2013;19: 249.
12. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012; 271: 111-121.
13. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9: 542-548.
14. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013; 93: 252-259.
15. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of nonsmall- cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-1049.
16. Dako Receives FDA Approval for use of EGFR PharmDx with Vectibix [Product Release]. King of Prussia, PA: Advance Healthcare Network for Laboratory. 5 October 2006. http://laboratory-manager.advanceweb.com/Article/Dako-Receives-FDA-Approval-for-Use-of-EGFR-pharmDx-with-Vectibix.aspx (8 October 2014, date last accessed).
17. FDA Approval for Cetuximab [National Cancer Institute Web Site Announcement]. Bethesda, MD: US National Institutes of Health/Food and Drug Administration; 6 July 2102. http://www.cancer.gov/cancertopics/druginfo/fda-cetuximab (8 October 2014, date last accessed).
18. FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer [Press Release]. Basel, Switzerland: F. Hoffmann-La Roche Ltd; 2014. 15 May 2013. http://www.roche.com/media/media_releases/med-cor-2013-05-15b.htm (8 October 2014, date last accessed).
19. Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4113-4120.
20. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
21. Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: what is there on the horizon?. J Carcinog 2013;12: 7.
22. Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics 2013; 7: 91-101.
23. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012;2012: 737981.
24. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev 2012 Dec 7 [epub ahead of print], doi: 10.3402/nano.v3i0.18496.
25. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012; 15: 183-210.
26. Antony AC. Folate receptors. Annu Rev Nutr 1996; 16: 501-521.
27. Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci 2006; 11: 506-519.
28. Zhao R, op-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011; 31: 177-201.
29. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443.
30. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissuetargeted therapeutics?. Cancer Metastasis Rev 2007; 26: 141-152.
31. Bianchi E, Doe B, Goulding D, Wright GJ. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature 2014; 508: 483-487.
32. O'Shannessy DJ, Yu G, Smale R et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012; 3: 414-425.
33. Shia J, Klimstra DS, Nitzkorski JR et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008; 39: 498-505.
34. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?. Int J Cancer 2006; 119: 243-250.
35. Tian Y, Wu G, Xing JC et al. A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol 2012;13: 30.
36. Kane MA, Elwood PC, Portillo RM et al. Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 1988; 81: 1398-1406.
37. Miotti S, Bagnoli M, Tomassetti A et al. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci 2000; 113(Pt 2): 349-357.
38. Bottero F, Tomassetti A, Canevari S et al. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 1993; 53: 5791-5796.
39. Figini M, Ferri R, Mezzanzanica D et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 2003; 10: 1018-1025.
40. Jhaveri MS, Rait AS, Chung KN et al. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 2004; 3: 1505-1512.
41. Lin J, Spidel JL, Maddage CJ et al. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther 2013; 14: 1032-1038.
42. Chen YL, Chang MC, Huang CY et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012; 6: 360-369.
43. Despierre E, Lambrechts S, Leunen K et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 2013; 130: 192-199.
44. Crane LM, Arts HJ, van OM et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol 2012; 35: 9-18.
45. Toffoli G, Russo A, Gallo A et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998; 79: 121-126.
46. Bremer RE, Scoggin TS, Somers EB et al. Interobserver agreement and assay reproducibility of folate receptor alpha expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target. Arch Pathol Lab Med 2013; 137(12): 1747-1752.
47. Hartmann LC, Keeney GL, Lingle WL et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007; 121: 938-942.
48. Kobel M, Madore J, Ramus SJ et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 2014; 111(12): 2297-2307.
49. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008; 27: 655-664.
50. Luyckx M, Votino R, Squifflet JL, Baurain JF. Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer. Int J Womens Health 2014; 6: 351-358.
51. Polley MY, Freidlin B, Korn EL et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 2013; 105: 1677-1683.
52. Parker N, Turk MJ, Westrick E et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005; 338: 284-293.
53. Basal E, Eghbali-Fatourechi GZ, Kalli KR et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009;4: e6292.
54. O'Shannessy DJ, Somers EB, Palmer LM et al. Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res 2013;6: 29.
55. O'Shannessy DJ, Gustavson M, Chandrasekaran LK et al. Prognostic significance of FRA expression in epithelial cancers using AQUA® technology. Biomark Med 2013; 7: 933-946.
56. Iwakiri S, Sonobe M, Nagai S et al. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008; 15: 889-899.
57. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-892.
58. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8: 277-302.
59. Schwarz RF, Ng CK, Cooke SL et al. Spatial and temporal heterogeneity in highgrade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015;12:e1001789.
60. Leamon CP, Parker MA, Vlahov IR et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99 m)Tc-based radiopharmaceutical. Bioconjug Chem 2002; 13: 1200-1210.
61. Fisher RE, Siegel BA, Edell SL et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008; 49: 899-906.
62. Mathias CJ, Wang S, Low PS et al. Receptor-mediated targeting of 67Gadeferoxamine- folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol 1999; 26: 23-25.
63. Wang S, Luo J, Lantrip DA et al. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug Chem 1997; 8:673-679.
64. Guo W, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999; 40:1563-1569.
65. Siegel BA, Dehdashti F, Mutch DG et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003; 44: 700-707.
66. van Dam GM, Themelis G, Crane LM et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first inhuman results. Nat Med 2011; 17: 1315-1319.
67. AlJammaz I, Al-Otaibi B, Al-Rumayan F et al. Development and preclinical evaluation of new (124)I-folate conjugates for PET imaging of folate receptorpositive tumors. Nucl Med Biol 2014; 41: 457-463.
68. Edelman MJ, Bonomi P, Harb W et al. The co-development of a folate receptor targeted drug conjugate vintafolide (EC145) and a folate receptor targeted imaging agent 99mTc-etarfolatide (EC20) in the treatment of advanced adenocarcinoma NSCLC. J Thorac Oncol 2012; 7(suppl 1): S63.
69. Morris RT, Joyrich RN, Naumann RW et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann Oncol 2014; 25: 852-858.
70. Edelman MJ, Harb WA, Pal SE et al. Multicenter trial of EC145 in advanced, folatereceptor positive adenocarcinoma of the lung. J Thorac Oncol 2012; 7:1618-1621.
71. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013; 31: 4400-4406.
72. Maurer AH, Elsinga P, Fanti S et al. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med 2014; 55: 701-704.
73. Pribble P, Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 2012; 21: 755-761.
74. Reddy JA, Dorton R, Westrick E et al. Preclinical evaluation of EC145, a folatevinca alkaloid conjugate. Cancer Res 2007; 67: 4434-4442.
75. Armstrong DK, White AJ, Weil SC et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013; 129: 452-458.
76. Thomas A, Maltzman J, Hassan R. Farletuzumab in lung cancer. Lung Cancer 2013; 80: 15-18.
77. Wen Y, Graybill WS, Previs RA et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 2015; 21: 448-459.
78. Gibbs DD, Theti DS, Wood N et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005; 65: 11721-11728.
79. Kamen BA, Smith AK. Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 2012; 70: 113-120.
80. Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer [News Release]. Tokyo, Japan: Eisai Co., Ltd. 11 January 2013. http://www.eisai.com/news/news201305.html (8 October 2014, date last accessed).
81. Vergote I, Armstrong D. Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum sensitive ovarian cancer in first relapse. Int J Gynecol Cancer 2013; 23(8 suppl): 11.
82. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015; 34: 41-52.
83. Gould HJ, Mackay GA, Karagiannis SN et al. Comparison of IgE and IgG antibodydependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999; 29: 3527-3537.
84. Karagiannis SN, Wang Q, East N et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003; 33: 1030-1040.
85. Josephs D, Rudman S, Karagiannis P et al. MOv18 IgE for the therapy of folate receptor.a (FR.a) solid tumours: in preparation for clinical application. In Presented at the 10th National Cancer Research Institute Cancer Conference; 2-5 November 2014; Liverpool, UK.
86. Rudman SM, Josephs DH, Cambrook H et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 2011; 41: 1400-1413.
87. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004; 56: 1127-1141.
88. Leamon CP, Reddy JA, Vlahov IR et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121: 1585-1592.
89. Vlahov IR, Santhapuram HK, Kleindl PJ et al. Design and regioselective synthesis of a new generation of targeted chemotherapeutic. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006; 16: 5093-5096.
90. Vlahov IR, Leamon CP. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem 2012; 23: 1357-1369.
91. LoRusso PM, Edelman MJ, Bever SL et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol 2012; 30: 4011-4016.
92. Hanna N, Juhasz E, Cainap C. TARGET: a randomized phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive non-small cell lung cancer patients. Ann Oncol 2014; 25(suppl 5): v1-v41. LBA40PR.
93. Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial be Stopped for Futility Following Interim Analysis. West Lafayette, IN: Endocyte, Inc. 2 May, 2014. http://investor.endocyte.com/release detail.cfm?releaseid=844838. (27 April 2015, date last accessed).
94. Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe. West Lafayette, IN: Endocyte, Inc. 19 May 2014. http://investor.endocyte.com/releasedetail.cfm?releaseid=848856. (27 April 2015, date last accessed).